Enanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of staff

Plus, news about Innovent Biologics, Relmada Therapeutics, Zevra Therapeutics, Incyte and Bionical Emas: Enanta’s Ph2 win in RSV: The company’s oral N-protein inhibitor achieved a 1.4 log decline in viral load ...